Loading
Life sciences · Phase 3 Trial
ClinicalTrials.gov · October 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 3 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07900633). This is a study registration, not published results. Lead sponsor: Eli Lilly and Company. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 3000 participants (ESTIMATED). Conditions: Obesity, Overweight, Cardiovascular Diseases, Diabetes Mellitus, Type 2. Interventions: DRUG: Eloralintide; DRUG: Placebo. Primary outcome measures: Percent Change from Baseline in Body Weight , Baseline, Week 64; Change from Baseline in Hemoglobin A1c (HbA1c) , Baseline, Week 36. Brief summary: The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with a placebo in participants with obesity or overweight, type 2 diabetes, and increased cardiovascular risk.